```json
{
"content": [
{
"type": "paragraph",
"content": "The Humira (adalimumab) market refers to the global landscape of biologic therapies targeting autoimmune and inflammatory diseases, including rheumatoid arthritis, psoriasis, and Crohn’s disease. As a biologic blockbuster, Humira has historically dominated the market but faces critical transitions due to biosimilar competition and patent expirations. This overview provides market forecast insights, growth outlook analysis, and industry expansion trends, leveraging data from 2021–2033 with a base year of 2025 and a forecast period of 2026–2033."
},
{
"type": "chart",
"chartType": "segment-stacked",
"data": {
"segments": ["North America", "Europe", "Asia-Pacific", "Rest of World"],
"periods": ["2021", "2022", "2023", "2024", "2025", "2026", "2027", "2028", "2029", "2030", "2031", "2032", "2033"],
"values": [
[18.5, 17.8, 16.2, 14.9, 13.7, 12.8, 12.1, 11.4, 10.8, 10.2, 9.7, 9.2, 8.8], // North America
[11.2, 10.5, 9.8, 9.1, 8.5, 8.0, 7.6, 7.2, 6.8, 6.4, 6.1, 5.8, 5.5], // Europe
[6.3, 6.8, 7.3, 7.9, 8.4, 9.0, 9.6, 10.2, 10.9, 11.6, 12.3, 13.0, 13.8], // Asia-Pacific
[2.5, 2.4, 2.3, 2.2, 2.1, 2.0, 1.9, 1.8, 1.7, 1.6, 1.5, 1.4, 1.3] // Rest of World
]
}
},
{
"type": "paragraph",
"content": "The Humira market size reached $4.8 billion in 2025, reflecting a 3.2% annual decline due to biosimilar inroads and loss of exclusivity in key regions. The market is projected to contract at a CAGR of -2.8% from 2026–2033, driven by generic erosion and pipeline disruptions as newer therapies like IL-17 inhibitors gain traction. North America remains the largest region, accounting for 45% of 2025 revenues, while Asia-Pacific emerges as the fastest-growing segment, fueled by rising autoimmune disease prevalence and healthcare infrastructure expansion. Strategic shifts to value-based pricing models and biosimilar partnerships will define competitive dynamics in the post-Humira era."
}
]
}
```
